Purchase this article with an account.
F. Birnbaum, J. Schwartzkopff, C. Scholz, A. Reis, T. Reinhard; Systemic FK778 Prolongs Clear Graft Survival in the Rat Keratoplasty Model . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1283.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to prove the efficacy of the new immunosuppressive drug FK778 regarding clear graft survival following allogeneic orthotopic keratoplasty in rats.
67 penetrating keratoplasties were performed using Fisher rats (allogeneic groups) and Lewis rats (syngeneic group) as donors and Lewis rats as recipients: group 1 (n=11), allogeneic control without therapy; group 2 (n=12), syngeneic control; group 3 (n=11), Mycophenolate Mofetil (MMF) 40 mg/kg bw; group 4 (n=12), FK778 5 mg/kg bw; group 5 (n=12), FK778 10 mg/kg bw; group 6 (n=9), FK778 20 mg/kg bw. Four animals of each group were sacrificed for immunohistological evaluation on day 14 (CD3, CD4, CD8, CD45, CD161, granulocytes and macrophages). Therapy was administered orally for 18 days. The grafts were evaluated every 3 days by means of a scoring–system including opacity, edema and vascularisation. Graft rejection was defined as total opacity of the graft.
The mean rejection free graft survival was 11.4 days in group 1 (allogeneic control), 100 days (total follow–up–time) in group 2 (syngeneic control), 24.0 days in group 3 (MMF 40 mg/kg), 15.7 days in group 4 (FK778 5 mg/kg), 19.1 days in group 5 (FK778 10 mg/kg) and 25.4 days in group 6 (FK778 20 mg/kg).
Systemic immunosuppression with FK778 prolongs graft survival statistically significantly in allogeneic keratoplasty in rats. Efficacy of FK778 is comparable with that of MMF.
This PDF is available to Subscribers Only